There are several unsolved clinical ®ndings in patients with idiopathic pulmonary ®brosis (IPF); (i) predominance of ®brosis in the lower lung ®elds, (ii) digital clubbing, and (iii) patchy distribution of pulmonary ®brosis. To explain these unsolved problems, we hypothesized that regenerated or premature bronchoepithelial cells may circulate in the blood in patients with IPF. To prove this, we performed the reverse transcriptase-polymerase chain reaction (RT-PCR) for cytokeratin 19 (CK19) and pulmonary surfactant protein A (SPA) in peripheral blood in patients with IPF and pulmonary ®brosis associated with collagen vascular disorders. In addition, 20 patients with chronic pulmonary emphysema as a disease control and 19 normal volunteers were also evaluated for the existence of circulating bronchoepithelial cells.
Introduction
Idiopathic pulmonary ®brosis (IPF) is an in¯ammatory lung disease which is characterized by the accumulation of in¯ammatory cells and deposition of collagen resulting in lung remodelling. It has been reported that lung cancer is frequently associated with IPF and the prevalence of lung cancer in patients with IPF has been reported to be more than 30% (1) . Carcinogenesis is believed to involve multistep genetic mutations, and several gene mutations have been found in hyperplastic, metaplastic and dysplastic epithelium (2) . Recently, we and other investigators have demonstrated overexpression of p53 proteins in bronchoepithelial cells by immunostaining (3), suggesting that bronchoepithelial cells have some DNA damage. In addition, we also have reported that heterogeneous point mutations of p53 genes are observed in lung specimens in patients with pulmonary ®brosis (4) .
There are several unsolved clinical ®ndings in patients with IPF; (i) predominance of ®brosis in the lower lung ®elds, (ii) digital clubbing, and (iii) the patchy distribution of pulmonary ®brosis. To explain these unsolved problems, we hypothesized that regenerated or premature bronchoepithelial cells may circulate in the blood in patients with pulmonary ®brosis. If there are circulating bronchoepithelial cells able to release several cytokines and cause ®brosis, predominance of ®brosis in the lower lung ®elds as well as the patchy distribution of pulmonary ®brosis may be explained. If these circulating bronchoepithelial cells are trapped at the digits and release several growth factors, pathogenesis of digital clubbing may be explained. We therefore tested for the existence of the RNA which encodes the intermediate ®lament protein cytokeratin 19 (CK19) and surfactant protein A (SP-A) as a marker for bronchoepithelial cells in patients with IPF as well as patients with pulmonary ®brosis associated with collagen vascular disorders and compared them to patients with chronic pulmonary emphysema and healthy normal volunteers.
Materials and methods

SUBJECTS
Thirty-eight patients (aged between 34 to 81 years, median age 67Á5, 12 females and 26 males) with pulmonary ®brosis (IPF and pulmonary ®brosis associated with collagen vascular disorders), and 20 patients with chronic pulmonary emphysema (aged between 55 to 84 years, median age 76Á5, 1 female and 19 males) were entered in this study (Table 1) . Twenty-®ve of 38 patients (65Á8%) with pulmonary ®brosis, and all of chronic pulmonary emphysema patients were smokers. Eight patients were diagnosed to have pulmonary ®brosis associated with collagen vascular disorders [progressive systemic sclerosis (two), polymyositis/dermatomyositis (two), SjoÈ gren syndrome (one) rheumatoid arthritis (two), and systemic lupus erythematosus (one)], and 20 patients were diagnosed to have IPF. Patients were diagnosed as having pulmonary ®brosis by Raghu's criteria (5) . In addition, high-resolution computed tomography was performed in all patients, and diagnoses of pulmonary ®brosis as well as chronic pulmonary emphysema were con®rmed by two expert radiologists. High-resolution computed tomography ®ndings also demonstrated that there was no evidence of complicated lung cancer in any of the patients with pulmonary ®brosis. Histological con®rmation was obtained by open lung biopsy (N8) or transbronchial lung biopsy (N30). All patients with pulmonary ®brosis were diagnosed to be compatible with the usual interstitial pneumonia, histologically. All patients with pulmonary ®brosis associated with collagen vascular disorders had been treated with steroid hormone.
Nineteen age-matched normal volunteers (aged between 30 to 77 years, median age 66, seven females and 12 males) were also evaluated. Seven of them were smokers.
MONONUCLEAR CELL ISOLATION AND RNA EXTRACTION
Peripheral venous blood samples (10 ml) were obtained with a standard venepuncture technique using a heparinized tube. Mononuclear cells from peripheral blood samples were isolated using a Ficoll gradient as described previously (6, 7) . A well-characterized human adenocarcinoma cell line, PC3 was used in this study as the positive control. Total RNA was extracted by the Guanidinium thiocyanate phenol-chloroform method using a commercial RNA preparation kit (RNAsol TM B;TEL-TEST, INC., Friendswood, TX). The extracted RNA was dissolved in RNase-free water to 1Á0 mg/ml and stored at 7808C. The quantity and quality of the RNA preparations were determined by absorbance at 260 nm and 280 nm.
REVERSE TRANSCRIPTASE-POLYMERASE CHAIN REACTION (RT-PCR)
Reverse transcriptase (RT) reaction was prepared in a ®nal volume of 20 ml and contained 1Á0 mg of total RNA, 1 ml of 1 pmol/ml Oligo dT and 1 ml of RT enzyme (SUPER-SCRIPT TM II RNase H 7 Reverse Transcriptase (RT;GIB-CO BRL, Gaithersburg, MD). PCR reaction was performed in a ®nal volume of 50 ml, contained reaction buer, dNTP (0Á25 mM of each), Taq 9) . The cycling conditions of the PCR for CK19 were as follows; 948C for 1 min, 688C for 2 min, for 15 cycles for the ®rst PCR and 35 cycles for the second PCR. The ®rst PCR product was a 1069 bp fragment and the second PCR product was a 409 bp fragment.
SPA-speci®c oligonucleotide primers were as follows; S: 5'-GAAGGACGTTTGTGTTGGAA-3' and AS: 5'-TGGATTCCTTGGGACAGCAA-3' (10). The cycling conditions of the PCR for SPA was as follows; 948C for 1 min, 548C for 1Á5 min, 728C for 2 min, for 45 cycles. The PCR product generated a 439 bp fragment.
Integrity of RNA and adequate cDNA synthesis was con®rmed by determining the presence of glyceraldehyde phosphate dehydrogenase (GAPDH) mRNA in the same sample, using primers 5'-GTCAACGGATTTGGTCTG-TATT-3' and 5'-AGTCTTCTGGGTGGCAGTGAT-3' as reported previously (11) . The cycling conditions were as follows; 948C for 1 min, 568C for 2 min, and 728C for 2 min, for 20 cycles.
All PCR reactions were preceded by a denaturation step at 948C for 3 min, and were terminated by a 10 min extension at 728C. These PCR were performed in a thermocycler (SANTHERMOPCR; Sanko Junyaku Co., Ltd., Tokyo, Japan).
PCR ampli®cation products were electrophoretically separated on 2% agarose gel and visualized by ethidium bromide staining. In addition, nucleotide sequences of ampli®ed products were sequenced. Sequence analysis was performed using an ABI PRISM 377 DNA Sequencer (ABI, Foster City, CA) with BigDye Terminator Cycle Sequencing Ready Reaction (ABI, Foster City, CA), and con®rmed that the ampli®ed products were identical to the expected sequences of cDNA of CK19 as well as SPA. 
Results
By RT-PCR analysis for GAPDH, mRNA for GAPDH was detected in all samples (data not shown). By RT-PCR analysis for CK19, ampli®ed products of 409 bp were clearly demonstrated (Fig. 1) . The size of ampli®ed products from blood samples were the same as that of PC3 (PLATE 1). Ampli®ed products were demonstrated in 12 of 38 blood samples (31Á6%) of patients with pulmonary ®brosis, seven of 20 blood samples (35Á0%) in chronic pulmonary emphysema, and four of 19 samples (21Á1%) of normal volunteers (Fig. 1 , Table 2 ). In addition, the quantity of CK19 mRNA for PC3 (per 1 mg/1 ml total RNA) is about 10 6 to 10 7 times higher than that of peripheral blood samples (data not shown). Sequence analysis demonstrated that all these ampli®ed products were part of cDNA of CK19.
By RT-PCR analysis for SPA, ampli®ed products of 439 bp were clearly demonstrated, and the size of ampli®ed products from blood samples were the same as that of PC3 (Fig. 2) . Ampli®ed products were demonstrated in eight of 38 (21Á1%) blood samples of IPF (Table 2 ). In contrast, SPA mRNA were not detected in any blood samples obtained from patients with chronic pulmonary emphysema or normal volunteers ( Table 2 ). In addition, the quantity of SPA mRNA for PC3 (per 1 mg/1 ml total RNA) was about 10 6 to 10 7 times higher than that of peripheral blood samples (data not shown). Sequence analysis demonstrated that all these ampli®ed products were part of cDNA for SPA. The number of patients who expressed mRNA of SPA was 8. However, seven of those eight did not express mRNA of CK19 (Table 2) .
There was no relationship between the existence of clubbed ®nger and expression of mRNA for CK19 or expression of mRNA for SPA (Table 1 ).
Discussion
In the past several years, the possibility of using RT-PCR analysis to detect micrometastatic cancer cells has received increasing attention (8±10, 12±16). A variety of genes (for example cytokeratin 8, CK19, cytokeratin 20, carcinoembryonic antigen, MUC 1, and SPA) have been evaluated for their ability to act as markers of malignant cells in the lymph nodes, bone marrow, and blood of patients with cancer (9,10).
Among these varieties of genes, the most extensively studied gene is CK19, and it has been shown to be widely expressed in breast, colon, small and non-small cell lung, and prostate cancer cells (16, 17) . Therefore, we attempted to detect the CK19 mRNA in serum from patients with IPF.
In this report, we carefully assessed the presence of illegitimate CK19 transcripts. In 1999, Ruud et al. (18) have reported a novel pseudogene. Therefore, we used new primer sets for nested PCR to avoid the ampli®cation of two known pseudogenes of CK19 (18, 19) . In our study, RT-PCR analysis showed that CK19 was expressed in 12 of 38 blood samples (31Á6%) in pulmonary ®brosis, seven of 20 blood samples (35Á0%) in chronic pulmonary emphysema, and four of 19 blood samples (21Á1%) in normal volunteers. There are con¯icts concerning the usefulness of CK19 mRNA to detect circulating cancer cells. Several reports have described that low levels of CK19 are detected in non-epithelial tissues such as endothelial cells and ®broblasts (6, 9, 15, 16, 20, 21) . Recently, Bustin et al. have reported mRNA for CK19 is expressed in 30% of blood samples taken from healthy volunteers (22) as observed in our study. We concluded that it was unsuitable to use CK19 mRNA to detect circulating bronchoepithelial cells, even if the ampli®cation of CK19 pseudogenes was avoided.
Pulmonary surfactant plays an important role in lowering the surface tension in the alveoli and therefore prevents lung collapse at low lung volumes. Surfactant is a lipoprotein complex and consists primarily of lipids (90%) and 5±10% proteins. Surfactant proteins (SP) 7A, 7B, 7C, and 7D are synthesized and secreted by alveolar type II cells or bronchiolar Clara cells (23±27). It has been reported that SPA is a lung-speci®c protein (28, 29) . Saitoh et al. (10) have reported that RT-PCR of the SPA gene transcript in pleural eusion is useful for the diagnosis of primary lung adenocarcinoma. In addition, Betz et al. (24) have reported that the SPA gene is detected in metastatic and micrometastatic pulmonary adenocarcinomas by using RT-PCR from paratracheal and subcarinal lymph nodes. Although there are few reports that have described the RT-PCR for SPA, it is con®rmed that SPA is useful for the diagnosis of primary lung adenocarcinoma.
Importantly, in the present study, RT-PCR analysis showed that SPA was expressed in eight of 38 blood samples (21Á1%) in patients with pulmonary ®brosis. In contrast, SPA-expressing cells were not detected in patients with chronic pulmonary emphysema or normal volunteers. In addition, seven of those eight did not express mRNA of CK19. Since SPA is a lung-speci®c protein, this discrepancy suggested that the expression of mRNA of CK19 may not have re¯ected the circulating bronchoepithelial cells. However, our present study strongly suggests that there were some circulating bronchoalveolar cells expressing mRNA of SPA in the peripheral blood of patients with pulmonary ®brosis. There are some reports which have described the presence of non-neoplastic epithelial cells in peripheral blood. Castells et al. have described that in¯ammatory bowel disease has detectable CEA mRNA expression in the blood. This evidence indicates the presence of nonneoplastic epithelial colonic cells in blood (30) . In addition, Hillaire et al. have also reported detectable mRNA for albumin in the blood obtained from patients with hepatitis that suggests the presence of normal hepatocytes in the blood (31) . From these reports, it might be reasonable to speculate that some bronchoepithelial cells are present in the blood of patients with pulmonary ®brosis.
The clinical signi®cance of the existence of SPA expressing bronchoepithelial cells in blood should be discussed. Based on results of RT-PCR for SPA, we speculated that some circulating bronchoepithelial cells may play a role in the repair of the injured bronchoepithelial cells. In addition, it can also be speculated that the detection of circulating bronchoepithelial cells re¯ected lung cancer which had been previously unproven clinically. At present, it is unclear whether these circulating bronchoepithelial cells were derived from the early lung cancer in pulmonary ®brosis or only from damaged epithelial cells which migrated into the capillary following lung injury. It can also be speculated that these circulating bronchoepithelial cells were (7) CK 19 mRNA (7) SPA mRNA() CK 19 mRNA (7) SPA mRNA (7) IPF and PF-CVD (N38) 1 premature stem cells derived from a relatively normal lung to repair the injured epithelium quickly and eciently. Future studies including follow up of the clinical course of patients in whom SPA expressing bronchoepithelial cells are detected will be required.
In conclusion, we demonstrate circulating broncho epithelial cells expressing mRNA for SPA in patients with pulmonary ®brosis (IPF and pulmonary ®brosis associated with collagen vascular disorders). Circulating broncho epithelial cells in pulmonary ®brosis may have played a contributory role in the pathogenesis of IPF.
